NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free VVOS Stock Alerts $4.83 +0.18 (+3.87%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.31▼$4.8550-Day Range$4.26▼$7.5552-Week Range$2.73▼$48.79Volume113,892 shsAverage Volume117,388 shsMarket Capitalization$6.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vivos Therapeutics alerts: Email Address Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Vivos Therapeutics Stock (NASDAQ:VVOS)Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.Read More VVOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VVOS Stock News HeadlinesMarch 28, 2024 | globenewswire.comVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateMarch 28, 2024 | globenewswire.comVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.February 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesFebruary 18, 2024 | investing.comVivos Therapeutics secures $4 million through warrant exerciseFebruary 15, 2024 | finance.yahoo.comVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsFebruary 15, 2024 | proactiveinvestors.comVivos Therapeutics sees gross proceeds of $4M from exercise of warrantMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.February 12, 2024 | finance.yahoo.comVivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market DisruptionsFebruary 6, 2024 | finanznachrichten.deVivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesFebruary 6, 2024 | finance.yahoo.comVivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesJanuary 8, 2024 | finance.yahoo.comVivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSADecember 11, 2023 | proactiveinvestors.comVivos Therapeutics announces women-led airway health eventDecember 11, 2023 | finance.yahoo.comVivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”December 1, 2023 | proactiveinvestors.comVivos Therapeutics severe sleep apnea treatment’s a ‘breakthrough’, says CEONovember 30, 2023 | benzinga.comThinking about buying stock in Minim Inc, Walmart, Farfetch Ltd, Qualcomm, or Vivos Therapeutics Inc?November 30, 2023 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Down 35% Today?November 30, 2023 | msn.comPhilips shares slump as FDA says sleep product may overheatNovember 29, 2023 | proactiveinvestors.comVivos Therapeutics: Who is the medical device company creating frenzy in the markets?November 29, 2023 | proactiveinvestors.comVivos Therapeutics receives first ever FDA 510(k) clearance...Vivos Therapeutics receives first ever FDA 510(k) clearance for...November 29, 2023 | msn.comVivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearanceNovember 29, 2023 | finance.yahoo.comUPDATE 2-US FDA clears Vivos Therapeutics' oral device for sleep apneaNovember 29, 2023 | finance.yahoo.comVivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apneaNovember 29, 2023 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Up 290% Today?November 29, 2023 | reuters.comUS FDA clears Vivos Therapeutics' oral device treatment for sleep apneaNovember 29, 2023 | markets.businessinsider.comVivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep ApneaSee More Headlines Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/28/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:VVOS CUSIPN/A CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees154Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,840,000.00 Net Margins-106.28% Pretax Margin-106.27% Return on Equity-508.27% Return on Assets-129.15% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual Sales$16.02 million Price / Sales0.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / Book0.99Miscellaneous Outstanding Shares1,330,000Free Float1,204,000Market Cap$6.30 million OptionableOptionable Beta8.04 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. R. Kirk Huntsman (Age 66)Co-Founder, Chairman of the Board & CEO Comp: $454.05kMr. Bradford K. Amman (Age 62)CFO, Treasurer & Secretary Comp: $297.23kMr. Todd HuntsmanCo-Founder & Senior VP of Product and TechnologyMs. RaeAnn ByrnesCo-Founder and Senior VP of Events & Clinical Advisory ServicesMs. Susan McCulloughCo-Founder & Executive VP of OperationsMs. Julie GannonSenior VP of Strategic Sales & Marketing and Investor Relations OfficerMr. Nicholas M. DeGennaroSenior Vice President of Medical Integration DivisionMs. Ruth HembreeSenior Vice President of Practice ServicesMs. Stephanie HuebnerSenior Vice President of Dental Service IntegrationMr. John BallardSenior Vice President of TechnologyMore ExecutivesKey CompetitorsAcutus MedicalNASDAQ:AFIBTitan MedicalNASDAQ:TMDIFSharps TechnologyNASDAQ:STSSGlucoTrackNASDAQ:GCTKMinerva SurgicalNASDAQ:UTRSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 604,436 shares on 3/11/2024Ownership: 0.795%Vanguard Group Inc.Sold 604,436 shares on 2/15/2024Ownership: 0.794%Armistice Capital LLCBought 57,000 shares on 2/13/2024Ownership: 4.286%Strategic Wealth Investment Group LLCSold 3,090,916 shares on 1/16/2024Ownership: 9.683%Ronald Kirk HuntsmanBought 560 shares on 6/20/2023Total: $7,420.00 ($13.25/share)View All Insider TransactionsView All Institutional Transactions VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed in 2024? Vivos Therapeutics' stock was trading at $12.44 at the beginning of the year. Since then, VVOS stock has decreased by 61.2% and is now trading at $4.83. View the best growth stocks for 2024 here. When is Vivos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our VVOS earnings forecast. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) issued its earnings results on Monday, November, 15th. The company reported ($6.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by $2.50. The company had revenue of $4.55 million for the quarter, compared to analyst estimates of $4.50 million. Vivos Therapeutics had a negative trailing twelve-month return on equity of 508.27% and a negative net margin of 106.28%. When did Vivos Therapeutics' stock split? Vivos Therapeutics's stock reverse split before market open on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. Who are Vivos Therapeutics' major shareholders? Vivos Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Strategic Wealth Investment Group LLC (9.68%), Armistice Capital LLC (4.29%), Vanguard Group Inc. (0.80%), Vanguard Group Inc. (0.79%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford K Amman and Ronald Kirk Huntsman. View institutional ownership trends. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VVOS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.